SPY362.06-1.61 -0.44%
DIA296.62-2.62 -0.88%
IXIC12,198.74-7.11 -0.06%

Lilly And Ypsomed Collaborate To Advance An Automated Insulin Delivery System For People With Diabetes

Eli Lilly and Company (NYSE:LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the

· 11/19/2020 06:47

Eli Lilly and Company (NYSE:LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.

Ypsomed's insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife™ YpsoPump®, this pump stands out for its small size and its unique, icon-based touch screen. Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring (CGM) and automated insulin delivery technology, in the United States and Europe. This pump will use pre-filled insulin cartridges for Lilly's rapid-acting insulins.

"Lilly is committed to delivering solutions that meet the needs of the diabetes community and providing more options to help them manage their diabetes," said Marie Schiller, vice president of product development for Connected Care and Insulins at Lilly. "People who use insulin, along with their healthcare providers, need simple, effective tools that lead to improved outcomes, and Ypsomed is developing an automated insulin delivery system with several exciting features that can help meet that need."

Ypsomed plans to submit a version of the mylife YpsoPump for clearance to the U.S. Food and Drug Administration for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.

"We are thrilled to partner with Lilly to bring our insulin pump to the United States and deliver improved outcomes to people with diabetes through connected solutions," said Simon Michel, CEO of Ypsomed. "Managing diabetes with insulin is already complex enough, so we developed this insulin pump to be easy to learn and easy to operate. Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms. Partnering with Lilly to bring a holistic platform to market is an important next step in this journey that started in 1984 by introducing the world's first micro insulin pump to the market."

About Diabetes
Approximately 34 million Americans1 (just over 1 in 10) and an estimated 463 million adults worldwide2 have diabetes. Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone1. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more. For the latest updates, visit http://www.lillydiabetes.com/ or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS.